[Bactericidal activity of cefpiramide on P. aeruginosa using an in vitro pharmacokinetic simulation model].

Cefpiramide (CPM) is a new cephalosporin with good activity against Pseudomonas. Sustained high serum concentrations are observed. We studied CPM killing kinetics using an in vitro model that simulates the pharmacokinetic profile observed in humans following a single intramuscular injection.

[Beta-lactamase induction in Pseudomonas aeruginosa by cefpiramide and 3 other antipyocyanic cephalosporins].

Cefpiramide (SR 95445) (CPM) is a new cephalosporin with activity against Pseudomonas and a good bioavailability following parenteral administration. This drug is a first rather than second choice treatment in Pseudomonas infections. For this reason, investigation into cefpiramide's capacity to induce beta-lactamase production is especially interesting.

Comparative studies of lipopolysaccharide and exopolysaccharide from a virulent strain of Pseudomonas solanacearum and from three avirulent mutants.

The composition of the Pseudomonas solanacearum lipolysaccharide (LPS) was found to be similar to that described for the LPS of enterobacteria. The lipid A contained fatty acids and glucosamine in a molar ratio of 5:2. The LPS fraction contained 2-keto-3-deoxyoctulosonic acid, L-glycero-D-mannoheptose, hexoses (glucose, rhamnose, and glucosamine), and a pentose (xylose).

[Chemical composition of the Pseudomonas solanecearum lipopolysaccharide].

The structure of Pseudomonas solanacearum lipopolysaccharide is similar to those described for the LPS of enterobacteria. The lipid A contains fatty acids and glucosamine (5 fatty acids for 2 glucosamine residues). The polysaccharide part contains 2-keto-3-deoxy-octulosonate, L-glycero-D-mannoheptose, hexoses (glucose, rhamnose, glucosamine) and a pentose (xylose).